Susan E. Erdman
Research Support
Funding
- R01 CA108854 07: ROLE OF IL10 AND TGFB1 IN COLON CANCER; PI: ERDMAN, SUSAN
- U01 CA164337:
GI TRACT DYSBIOSIS AND BREAST CANCER; PI: ERDMAN, SUSAN
- ES002109 32: PILOT PROJECT PROGRAM, CEHS; PI: ERDMAN, SUSAN
AND ALM, ERIC
Collaborations
The Erdman Laboratory works with leading researchers and
institutions worldwide:
- Cancer Prevention Institute of California
- Columbia University
- Harvard Medical School
- MIT
- Thessoliniki University
- U. Mass Medical, MA
- Yale University, CT
- Dana Farber, MA
Research Interests
We work with a synergistic team of scientists with
diverse backgrounds, training and institutional environments with
the unified goal of targeting inflammatory processes in disease and in health.
My background in Comparative Medicine at Massachusetts Institute of
Technology (MIT) and postdoctoral training from Harvard School of
Public Health provides unique expertise in animal models of
immunology and cancer, integrated with a global perspective on human
health.
Regulatory T Cells (TREG) Inhibit non-B non-T Colitis and Cancer
Brief Key Findings
- Regulatory TREG cells inhibit non-B non-T colitis (2001) [1].
- Gut bacteria-triggered innate immunity is sufficient for cancer (2003) [3].
- Enteropathogenic gut bacteria trigger extra-intestinal cancer (2006) [6].
- Earlier microbe exposures facilitate immune balance and prevent cancer (2006) [6].
- Feeding of sterile microbes is sufficient for immune balance (2010) [15].
- Adoptive transfer of immune cells increases lifespan (2010) [15].
- Gut bacteria, IL10, and mucosal immunity unify cancer with other inflammatory disorders (2010) [7], [17].
- Oral microbe therapy heals wounds 2X faster, promotes healthful aging, healthy skin and hair, prevents age-associated weight gain, and may prevent some types of cancer. (2013) [21], [19], [18].
